Andrew Hirsch is the CEO of C4 Therapeutics, Inc., a biotechnology company he joined in October 2020. He earned his M.B.A. from the Tuck School at Dartmouth and has a B.A. in Economics from the University of Pennsylvania. Before leading...

Andrew Hirsch is the CEO of C4 Therapeutics, Inc., a biotechnology company he joined in October 2020. He earned his M.B.A. from the Tuck School at Dartmouth and has a B.A. in Economics from the University of Pennsylvania. Before leading C4, he was the Chief Financial Officer at Agios Pharmaceuticals, where he helped develop corporate strategies. Hirsch has also been the CEO of BIND Therapeutics, another biotech firm. His experience spans years in various leadership roles at companies like Biogen and Avila Therapeutics. Under his watch, C4 Therapeutics has focused on innovative treatments in clinical development, specifically protein degradation therapies, which have the potential to revolutionize cancer treatment. In 2023, his total compensation was around $665,200, which includes a significant amount of restricted stock units tied to company performance. He is also known for strategic insider trading, peaking his holdings value at about $3.19 million last September. Throughout his career, Hirsch remains committed to aligning executive interests with company success.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other C4 Therapeutics CEOs

C

Andrew Hirsch

Ex-CEO of C4 Therapeutics

Education

M.B.A. from the Tuck School at Dartmouth College; B.A. in Economics from the University of Pennsylvania

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

CEO of C4 Therapeutics for

2 years 11 months (Oct 2020 - Sep 2023)

Previous Experience

Chief Financial Officer at Agios Pharmaceuticals, Inc.; President and Chief Executive Officer of BIND Therapeutics, Inc.; Chief Financial Officer at Avila Therapeutics, Inc.; roles at Biogen Inc.

Rivals

Competitors/colleagues of Andrew Hirsch

Holdings

See how much did Andrew Hirsch make over time.

As of the latest records, Andrew Hirsch holds approximately $3.19 million in company shares. His stock holdings have seen fluctuations over the years. Notably, his most substantial wealth in C4 was around October 2023, where it peaked at approximately $3.19...

As of the latest records, Andrew Hirsch holds approximately $3.19 million in company shares. His stock holdings have seen fluctuations over the years. Notably, his most substantial wealth in C4 was around October 2023, where it peaked at approximately $3.19 million. Since taking the role of CEO in 2020, Hirsch's confidence in the future of C4 is reflected in his consistent buying patterns throughout the years and strategic trading decisions, showcasing his strong belief in the company's vision and potential. He has effectively leveraged these opportunities, moving between $600K and over $1 million monthly during certain periods, signaling a keen insight into market trends and performance.

Insider Trading

See recent insider trades of Andrew Hirsch.

CCCC

103,400 shares

CCCC

Feb 14, 2024

Received

CCCC

81,600 shares

CCCC

Feb 15, 2023

Received

CCCC

$84.00K

CCCC at $8.40/share

Apr 12, 2022

Purchase

Compensation History

See how much did Andrew Hirsch make over time.

Andrew Hirsch's compensation package reflects his role's responsibilities and the company’s performance. In 2023, he earned about $665,200, which includes a base salary of $639,000. His bonus structure didn't yield additional payouts this year, as he received no bonus. However, he did gain from the vesting of 81,600 restricted stock units (RSUs) valued at around $470,832. These equity awards align with his goals as CEO to enhance shareholder value over the long term. Previous years showed more variability, especially in 2022, when his total compensation soared to approximately $2.6 million, largely due to performance-driven bonuses and stock awards linked to company milestones. The compensation framework indicates a strong focus on performance metrics related to clinical development and financial goals, clearly tied to the innovative work being done at C4.

Year

2023

Total Compensation

$1.12M

Salary

$639.00K

Board Justification

The compensation program is designed to align executive interests with company performance and stockholder returns, focusing on long-term value creation.

Bonus

$0.00

Board Justification

No bonus was awarded for 2023.

Other

$13.20K

Board Justification

This includes 401(k) matching contributions and other standard benefits.

Restricted Stock

$470.83K(81.6K RSU)

Board Justification

81,600 RSUs were granted in 2023, vesting annually over four years.

Performance Metrics

The performance metrics for 2023 included achieving corporate objectives related to clinical development and financial performance.

Other C4 Therapeutics CEOs

Here are other CEOs of C4 Therapeutics

Kendra Adams

CEO of C4 Therapeutics

September 2023 - Present